What is Zacks Research’s Forecast for Chemours Q3 Earnings?

The Chemours Company (NYSE:CC) – Investment analysts at Zacks Research dropped their Q3 2026 earnings per share (EPS) estimates for shares of Chemours in a research note issued to investors on Monday, May 19th. Zacks Research analyst R. Department now expects that the specialty chemicals company will post earnings per share of $0.74 for the quarter, down from their prior estimate of $0.78. The consensus estimate for Chemours’ current full-year earnings is $2.03 per share. Zacks Research also issued estimates for Chemours’ Q4 2026 earnings at $0.45 EPS.

Several other equities analysts also recently weighed in on the company. Royal Bank of Canada dropped their target price on Chemours from $17.00 to $14.00 and set an “outperform” rating for the company in a research report on Thursday, May 8th. Barclays dropped their target price on Chemours from $19.00 to $16.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 1st. Wall Street Zen cut Chemours from a “hold” rating to a “sell” rating in a research note on Wednesday. BMO Capital Markets decreased their price objective on Chemours from $34.00 to $27.00 and set an “outperform” rating for the company in a research note on Wednesday, February 19th. Finally, Morgan Stanley decreased their price objective on Chemours from $22.00 to $15.00 and set an “equal weight” rating for the company in a research note on Monday, May 12th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $17.56.

Chemours Stock Up 2.8%

Shares of NYSE:CC opened at $10.84 on Thursday. The company has a market capitalization of $1.62 billion, a price-to-earnings ratio of 19.02 and a beta of 1.76. The company has a current ratio of 1.68, a quick ratio of 0.92 and a debt-to-equity ratio of 6.70. The business has a 50-day moving average price of $12.05 and a 200 day moving average price of $16.08. Chemours has a 12-month low of $9.33 and a 12-month high of $27.31.

Chemours (NYSE:CC) last issued its quarterly earnings data on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.06). The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.36 billion. Chemours had a return on equity of 26.54% and a net margin of 1.51%. The firm’s revenue for the quarter was up .4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.32 earnings per share.

Chemours Announces Dividend

The firm also recently announced a dividend, which will be paid on Monday, June 16th. Investors of record on Monday, May 19th will be paid a dividend of $0.0875 per share. This represents a yield of 3.17%. The ex-dividend date of this dividend is Friday, May 16th. Chemours’s payout ratio is 175.00%.

Insider Buying and Selling

In other news, CFO Shane Hostetter purchased 4,450 shares of the business’s stock in a transaction on Monday, May 19th. The shares were bought at an average price of $11.28 per share, with a total value of $50,196.00. Following the completion of the transaction, the chief financial officer now directly owns 59,694 shares in the company, valued at approximately $673,348.32. This represents a 8.06% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.47% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CC. FNY Investment Advisers LLC acquired a new position in Chemours during the first quarter worth approximately $27,000. UMB Bank n.a. increased its holdings in shares of Chemours by 73.9% in the first quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company’s stock valued at $30,000 after purchasing an additional 948 shares during the period. Farther Finance Advisors LLC increased its holdings in shares of Chemours by 170.7% in the first quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company’s stock valued at $30,000 after purchasing an additional 1,444 shares during the period. SouthState Corp acquired a new position in shares of Chemours in the first quarter valued at approximately $34,000. Finally, Quadrant Capital Group LLC increased its holdings in shares of Chemours by 100.4% in the fourth quarter. Quadrant Capital Group LLC now owns 2,234 shares of the specialty chemicals company’s stock valued at $38,000 after purchasing an additional 1,119 shares during the period. Institutional investors and hedge funds own 76.26% of the company’s stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.